circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Q2 2019 Cytokinetics, Inc. Earnings Conference Call
    Aug 8, 2019 4:30 PM EDT

    Q2 2019 Cytokinetics, Inc. Earnings Conference Call
    Aug 8, 2019 4:30 PM EDT
  • Webcast
    X JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT

    JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Reports Second Quarter 2019 Financial Results
Completed Enrollment in GALACTIC-HF with More than 8,200 Heart Failure Patients Results from Phase 1 Study of CK-274 to be Presented at HFSA in September 2019 ; Phase 2 Clinical Trial Expected to Begin in Q4 SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
Preclinical Studies Show CK-3773274 Produces Exposure Related Effects on Cardiac Contractility in Healthy Animals and Mouse Models of Hypertrophic Cardiomyopathy and Support Therapeutic Hypothesis for Onset of Action and Reversibility in the Clinical Setting Figure: CK-3773274 decreased fractional
Toggle Summary Cytokinetics to Announce Second Quarter Results on August 8, 2019
SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on August 8, 2019 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
SOUTH SAN FRANCISCO, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator (FSTA) can decrease skeletal muscle fatigue by increasing the

EVENTS

There are currently no events to display.